Fortrea (FTRE) to Post Quarterly Earnings on Wednesday

Fortrea (NASDAQ:FTRE) is projected to announce its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect the company to announce earnings of $0.18 per share and revenue of $647.53 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:00 AM ET.

Fortrea (NASDAQ:FTRE) last announced its earnings results on Tuesday, May 5th. The company reported $0.16 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.13. The business had revenue of $636.50 million during the quarter, compared to the consensus estimate of $628.50 million. Fortrea had a positive return on equity of 9.51% and a negative net margin of 16.50%. On average, analysts expect Fortrea to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Fortrea Stock Performance

NASDAQ:FTRE opened at $17.91 on Wednesday. The company has a debt-to-equity ratio of 1.98, a quick ratio of 0.95 and a current ratio of 0.95. The company has a fifty day moving average of $16.12 and a two-hundred day moving average of $13.68. The stock has a market capitalization of $1.69 billion, a PE ratio of -3.65, a P/E/G ratio of 0.54 and a beta of 2.03. Fortrea has a fifty-two week low of $4.93 and a fifty-two week high of $18.67.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Sivia Capital Partners LLC acquired a new stake in shares of Fortrea in the second quarter valued at approximately $79,000. Abel Hall LLC acquired a new stake in shares of Fortrea in the 4th quarter worth $181,000. Scientech Research LLC purchased a new position in shares of Fortrea during the 3rd quarter worth $91,000. Focus Partners Wealth acquired a new position in Fortrea in the 1st quarter valued at about $80,000. Finally, Occudo Quantitative Strategies LP purchased a new position in shares of Fortrea during the 2nd quarter worth approximately $71,000.

Wall Street Analyst Weigh In

FTRE has been the subject of a number of research reports. Truist Financial set a $19.00 target price on shares of Fortrea in a research note on Wednesday, May 6th. Robert W. Baird set a $20.00 price target on shares of Fortrea in a research note on Wednesday, May 6th. Citigroup lifted their price objective on Fortrea from $16.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Mizuho boosted their price objective on Fortrea from $13.00 to $16.00 and gave the stock a “neutral” rating in a research note on Monday, July 13th. Finally, TD Cowen reissued a “buy” rating on shares of Fortrea in a report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Fortrea has an average rating of “Moderate Buy” and an average price target of $17.75.

Fortrea Company Profile

Fortrea, Inc is a global contract development and manufacturing organization (CDMO) that provides integrated solutions for pharmaceutical and biotechnology companies. Established as a spin-off from Thermo Fisher Scientific’s Pharma Services business in October 2023, Fortrea leverages a legacy of scientific expertise and manufacturing scale to support drug development from early-stage research through commercial production. The company’s comprehensive offerings address the complex needs of both small-molecule and biologics programs, making it a single source for clients seeking to accelerate timelines and manage costs.

Fortrea’s core services encompass analytical and formulation development, process optimization, clinical and commercial manufacturing, and packaging services.